Inventor
CASTONGUAY ROSELYNE
US34 patents
⚠️ This page may combine multiple inventors who share the name “CASTONGUAY ROSELYNE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ACCELERON PHARMA INC
31 patentsUS9809637B2Nov 7, 2017
Transforming growth factor beta receptor II fusion polypeptides
ACCELERON PHARMA INC19 citations92
US11028145B2Jun 8, 2021
ALK7:actriib heteromultimers and uses thereof
ACCELERON PHARMA INC4 citations84
US10738098B2Aug 11, 2020
ALK4:ActRIIB heteromultimers and uses thereof
ACCELERON PHARMA INC6 citations84
US10307455B2Jun 4, 2019
Activin type 2 receptor antibodies
ACCELERON PHARMA INC5 citations84
US10227393B2Mar 12, 2019
TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
ACCELERON PHARMA INC9 citations84
US11279746B2Mar 22, 2022
ALK4:ActRIIB heteromultimers and uses thereof
ACCELERON PHARMA INC2 citations73
US10906958B2Feb 2, 2021
TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
ACCELERON PHARMA INC2 citations73
US10227392B2Mar 12, 2019
ALK7:ActRIIB heteromultimers and uses thereof
ACCELERON PHARMA INC3 citations73
US10196434B2Feb 5, 2019
ALK4:ActRIIB heteromultimers and uses thereof
ACCELERON PHARMA INC3 citations73
US11059894B2Jul 13, 2021
ALK7 binding proteins and uses thereof
ACCELERON PHARMA INC1 citations72
US10501547B2Dec 10, 2019
ALK7 binding proteins and uses thereof
ACCELERON PHARMA INC3 citations72
US10316076B2Jun 11, 2019
Transforming growth factor-beta receptor type II fusion polypeptides
ACCELERON PHARMA INC3 citations72
US12545736B2Feb 10, 2026
ActRII-binding proteins and uses thereof
ACCELERON PHARMA INC0 citations62
US12421295B2Sep 23, 2025
TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
ACCELERON PHARMA INC0 citations62
US12258380B2Mar 25, 2025
ALK4:actriib heteromultimers and uses thereof
ACCELERON PHARMA INC0 citations62
US12054753B2Aug 6, 2024
Methods of treatment of muscular dystrophy with ALK4:ActRIIB heteromultimers
ACCELERON PHARMA INC0 citations62
US12042524B2Jul 23, 2024
Activin type 2 receptor binding proteins methods of making them
ACCELERON PHARMA INC0 citations62
US12024563B2Jul 2, 2024
ALK7 antagonists and uses thereof
ACCELERON PHARMA INC0 citations62
US11827689B2Nov 28, 2023
ALK7:ActRIIB heteromultimers and uses thereof
ACCELERON PHARMA INC0 citations62
US11708414B2Jul 25, 2023
ALK7 binding proteins and uses thereof
ACCELERON PHARMA INC0 citations62
US11440949B2Sep 13, 2022
TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
ACCELERON PHARMA INC1 citations62
US11008377B2May 18, 2021
Methods of treating a fibrotic disorder by administering transforming growth factor beta receptor II fusion polypeptides
ACCELERON PHARMA INC0 citations62
US11000565B2May 11, 2021
Methods of increasing muscle mass by administration of activin type 2 receptor antibodies
ACCELERON PHARMA INC0 citations62
US10981973B2Apr 20, 2021
Methods of treating a sclerotic disorder by administering a transforming growth factor beta receptor type II fusion polypeptide
ACCELERON PHARMA INC0 citations62
US10934532B2Mar 2, 2021
ALK4.ActRIIB heteromultimers
ACCELERON PHARMA INC0 citations62
US11590201B2Feb 28, 2023
Endoglin peptides to treat fibrotic diseases
ACCELERON PHARMA INC0 citations61
US10981972B2Apr 20, 2021
Endoglin polypeptides and uses thereof
ACCELERON PHARMA INC1 citations61
US12365736B2Jul 22, 2025
ALK7 binding proteins and uses thereof
ACCELERON PHARMA INC0 citations51
US11981738B2May 14, 2024
ALK7 binding proteins and uses thereof
ACCELERON PHARMA INC0 citations51
US12168683B2Dec 17, 2024
Binders of TGFβ-superfamily ligands and uses thereof
ACCELERON PHARMA INC0 citations47
US12103959B2Oct 1, 2024
Multispecific binders of TGFBeta-superfamily ligands and uses thereof
ACCELERON PHARMA INC0 citations47
BRIGHAM & WOMENS HOSPITAL INC
2 patentsUS10682392B2Jun 16, 2020
Methods for treating pulmonary hypertension with a TGF-beta type II receptor-FC fusion protein
BRIGHAM & WOMENS HOSPITAL INC4 citations73
US11951156B2Apr 9, 2024
Methods for treating pulmonary hypertension with a ligand binding domain of a TGF-beta type II receptor
BRIGHAM & WOMENS HOSPITAL INC1 citations62